#JPM2026 Post-Event Report

The JP Morgan Healthcare conference is a well-established bellwether for the biopharma market. It sets the tone – and expectations – for the year ahead. What did JP Morgan 2026 bring? Find out in Evaluate’s post-event round up which brings together the highlights, the trends and the sentiment about a year that many hope to be the turnaround that pharma and biotech needs.

Our experts have scrutinized the presentations to bring you detailed insights about the event and what it means for biotechs, pharma companies and life sciences investors.

Share:

Download today








#JPM2026 Post-Event Report

Your definitive guide to the biggest announcements and takeaways from this year’s most influential healthcare summit. See our roundup of mega cap, large cap, mid cap, small cap, and micro cap pharmaceutical companies.

Our experts have analyzed the trends, partnerships, and key presentations from the conference, providing insights you won’t find anywhere else.

Download the report now and stay ahead with unparalleled coverage and insights.

 

Upcoming Webinar

China Pipelines, Western Portfolios

Tuesday 14th July 3pm BST | 10am ET

Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.

Related Content